Notably, these trials reported decreased p-tau levels in both CSF and plasma, potentially supporting the amyloid cascade hypothesis by suggesting that Aβ accumulation modulates other AD pathologies, such as tau [36]. The gene discussed is MAPT; the disease is Alzheimer disease.